Login
$VIR
$9.62 +$0.04 (0.42%) After hours

$VIR SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Sawaf Aziz, EVP, Chief Financial Officer

Received 75,000 shares as a grant or award · Granted 150,000 Stock Option (Right to Buy)

16 Nov 2026 Form 4: Sabatini Brent, SVP, Chief Accounting Officer

Received 50,000 shares as a grant or award

16 Nov 2026 424B5
12 Nov 2026 424B5
12 Nov 2026 S-3ASR
10 Nov 2026 SCHEDULE 13G
09 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Vir Biotechnology, Inc. (the Company) is holding a virtual investor conference call at 5:30 a.m. PT / 8:30 a.m. ET on November 9, 2026, to discuss the topline results from the pivotal Phase 3 ECLIPSE 1 clinical trial evaluating monthly s...

06 Nov 2026 SCHEDULE 13D/A
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026

04 Nov 2026 Form 4: de Verneuil Vanina, EVP, General Counsel, Corp Sec

Sold 1,343 shares ($15.2K) · Sold 2,407 shares ($26.7K)

03 Nov 2026 144
02 Nov 2026 144
28 Oct 2026 Form 4: Topalian Suzanne Louise, Director

Received 12,731 shares as a grant or award · Granted 25,462 Stock Option (Right to Buy)

28 Oct 2026 Form 3: Topalian Suzanne Louise, Director

Holds 0 shares of Common Stock

28 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 26, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board fr...

27 Oct 2026 SCHEDULE 13G/A
14 Oct 2026 8-K: Unregistered Sales of Equity Securities; Other Events

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

08 Oct 2026 8-K: Other Events

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

06 Oct 2026 Form 3: Sawaf Aziz, EVP, Chief Financial Officer

Holds 0 shares of Common Stock

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support